Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy
associated with TMEM173-activating mutat and has received grants from the National
Health and Medical Research Council (NHMRC). DB Pyne has received a grant and
consulting honorarium from Danisco DuPont; has received payment for lectures from Sports
Dietitians Australia; and has received travel support from the Australian Swimming Coaches
Association. HS Warren has received grants from Griffith University. AJ Cox has consultant …